1471 related articles for article (PubMed ID: 8914208)
1. Biologic therapy of melanoma with cytokines and lymphocytes.
Bear HD; Hamad GG; Kostuchenko PJ
Semin Surg Oncol; 1996; 12(6):436-45. PubMed ID: 8914208
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma.
Garbe C
Melanoma Res; 1993 Aug; 3(4):291-9. PubMed ID: 7693093
[TBL] [Abstract][Full Text] [Related]
3. Current therapy for malignant melanoma.
Legha SS
Semin Oncol; 1989 Feb; 16(1 Suppl 1):34-44. PubMed ID: 2465575
[TBL] [Abstract][Full Text] [Related]
4. Cytokine-based therapy and biochemotherapy for advanced melanoma.
Atkins MB
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2353s-2358s. PubMed ID: 16609058
[TBL] [Abstract][Full Text] [Related]
5. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
[TBL] [Abstract][Full Text] [Related]
6. Biochemotherapy of melanoma.
Keilholz U
Forum (Genova); 2003; 13(2):158-65; quiz 189. PubMed ID: 14732882
[TBL] [Abstract][Full Text] [Related]
7. Increased non-major histocompatibility complex-restricted lytic activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cells.
Möller P; Möller H; Sun Y; Dorbic T; Henz BM; Wittig B; Schadendorf D
Cancer Gene Ther; 2000 Jul; 7(7):976-84. PubMed ID: 10917199
[TBL] [Abstract][Full Text] [Related]
8. Lessons from the clinical trials of interleukin-2.
Parkinson DR
Nat Immun Cell Growth Regul; 1990; 9(4):242-52. PubMed ID: 2215513
[TBL] [Abstract][Full Text] [Related]
9. Adoptive cellular therapy.
Hoffman DM; Gitlitz BJ; Belldegrun A; Figlin RA
Semin Oncol; 2000 Apr; 27(2):221-33. PubMed ID: 10768601
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of malignant melanoma.
Oratz R; Bystryn JC
Dermatol Clin; 1991 Oct; 9(4):669-82. PubMed ID: 1718648
[TBL] [Abstract][Full Text] [Related]
11. Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma.
Bukowski RM
Semin Oncol; 2000 Apr; 27(2):204-12. PubMed ID: 10768599
[TBL] [Abstract][Full Text] [Related]
12. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
13. [The value of interferons, interleukin-2 and tumor necrosis factor in the therapy of renal cell cancer].
Wirth M
Urologe A; 1991 Mar; 30(2):77-80. PubMed ID: 1711729
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of metastasized malignant melanoma].
Kamanabrou D
Praxis (Bern 1994); 2001 Mar; 90(10):391-6. PubMed ID: 11305184
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma.
Dréno B; Nguyen JM; Khammari A; Pandolfino MC; Tessier MH; Bercegeay S; Cassidanius A; Lemarre P; Billaudel S; Labarrière N; Jotereau F
Cancer Immunol Immunother; 2002 Nov; 51(10):539-46. PubMed ID: 12384805
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy as part of combinations for the treatment of cancer.
Mitchell MS
Int Immunopharmacol; 2003 Aug; 3(8):1051-9. PubMed ID: 12860162
[TBL] [Abstract][Full Text] [Related]
17. Cytokine-based therapy for melanoma: pre-clinical studies.
Shurin MR; Kirkwood JM; Esche C
Forum (Genova); 2000; 10(3):204-26. PubMed ID: 11007930
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients.
Labarrière N; Pandolfino MC; Gervois N; Khammari A; Tessier MH; Dréno B; Jotereau F
Cancer Immunol Immunother; 2002 Nov; 51(10):532-8. PubMed ID: 12384804
[TBL] [Abstract][Full Text] [Related]
20. Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.
Keilholz U; Stoter G; Punt CJ; Scheibenbogen C; Lejeune F; Eggermont AM
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S22-8. PubMed ID: 9457389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
